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Abstract 
 
Objective—The origin of the mesenchymal cells responsible for the intimal fibrosis in Systemic 
Sclerosis (SSc) has not been fully identified. Here, we investigated whether subendothelial 
mesenchymal cells may emerge through transdifferentiation of endothelial cells (EC) into 
myofibroblasts via endothelial-mesenchymal transition (EndoMT) in vitro and the signaling 
pathways involved in this process. 
 
Methods—Primary mouse pulmonary EC isolated by immunomagnetic methods employing 
sequential anti-CD34 and anti-CD102 antibody selection were cultured in monolayers. Cell 
morphology and diacetylated LDL uptake assays confirmed their EC characteristics. The induction 
of EndoMT was assessed by determination of α-smooth muscle actin (α-SMA), collagen type I, 
and VE-Cadherin expression and the expression of the transcriptional repressor Snail-1 was 
analyzed. The signaling pathways involved were examined employing small molecule kinase 
inhibitors and short RNA interference. 
 
Results—TGF-β1 induced α-SMA and type I collagen expression and inhibited VE-Cadherin. 
These effects were mediated by a marked increase in Snail-1 expression and were abolished by 
treatment with either the c-Abl tyrosine kinase inhibitor, imatinib mesylate or the protein kinase C 
δ (PKC-δ) inhibitor, rottlerin. The inihibitory effects of imatinib mesylate and rottlerin were 
mediated by inhibition of phosphorylation of GSK-3β at residue Ser9. These observations were 
confirmed employing short interfering RNA specific for c-Abl and PKC-δ. 
 
Conclusion—These results indicate that c-Abl and PKC-δ are crucial for TGF-β-induced 
EndoMT and that imatinib mesylate and rottlerin or similar kinase inhibitor molecules may be 
effective therapeutic agents for SSc and other fibroproliferative vasculopathies in which EndoMT 
plays a pathogenetic role. 
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endothelial-mesenchymal transition; transforming growth factor-β; Snail-1; α-smooth muscle 
actin; systemic sclerosis; pulmonary artery hypertension; c-Abl tyrosine kinase; imatinib mesylate; 
protein kinase C δ; rottlerin 
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Introduction 
 
Fibroproliferative vasculopathies characterized by accumulation of mesenchymal cells and 
fibrosis in the subendothelial space of medium size and small vessels are the pathological 
hallmark of a diverse group of disorders including transplant rejection and allograft 
vasculopathy (1), primary pulmonary hypertension (2), and systemic sclerosis (SSc) (3,4). 
The origin of the mesenchymal cells and myofibroblasts responsible for subendothelial 
intimal fibrosis remains elusive. Vessel wall resident fibroblasts and circulating 
mesenchymal cell progenitors, also known as fibrocytes, migrating into the vessel intima 
have been considered important sources. However, recent studies have shown that 
mesenchymal cells and myofibroblasts can also originate from endothelial cells in a process 
known as endothelial–mesenchymal transition (EndoMT) in which endothelial cells (EC) 
acquire a myofibroblastic phenotype (5,6). EndoMT has been reported to contribute to the 
myofibroblastic population in chronic pulmonary hypertension (7) and cardiac, renal, and 
pulmonary fibrosis (8–12), thus, the possibility that some of the fibrotic tissue-producing 
subendothelial mesenchymal cells responsible for the severe SSc fibroproliferative 
vasculopathy may also originate from endothelial cells is attractive. 
 
Transforming growth factor (TGF)-β1 plays a crucial role in tissue fibrosis and is implicated 
in the pathogenesis of numerous disorders including the fibroproliferative vasculopathies 
(13–17). Besides causing a potent stimulation of the expression of numerous genes 
participating in the fibrotic process, TGF-β is involved in the generation of myofibroblasts 
through epithelial to mesenchymal transition (EMT) (18–21) and EndoMT (7–12). Here, we 
examined the intracellular signaling pathways involved in TGF-β induced EndoMT in 
murine pulmonary EC. The results demonstrated that TGF-β1 caused a potent induction of 
α-SMA expression in murine pulmonary EC. This process was accompanied by a marked 
increase in the expression of the transcriptional repressor, Snail-1 and was abolished by 
treatment with the cAbl kinase inhibitor, imatinib mesylate or the PKC-δ inhibitor, rottlerin. 
The potent inhibition of TGF-β-induced α-SMA expression by small molecule c-Abl and 
PKC-δ inhibitors suggests that these or similar inhibitor molecules may be effective 
therapeutic agents for SSc fibroproliferative vasculopathy as well as for other pathologic 
conditions in which EndoMT plays a role. 
 
Materials and methods 
 
Materials 
Dulbecco’s modified Eagle’s medium (DMEM) was from Gibco (Carlsbad, CA). 
Glutamine, penicillin/streptomycin, sodium pyruvate, HEPES and non-essential amino acids 
were from Mediatech (Manassas, VA). Fetal bovine serum (FBS) was from Atlanta 
Biological (Lawrenceville, GA). Anti-CD34 and anti-CD102 antibodies were from BD 
Biosciences (Bedford, MA). Western blots and indirect immunofluorescence antibodies 
were: α-SMA (clone SPM332) and GAPDH (Abcam, Cambridge, MA), VE-Cadherin, 
collagen1A1, Snail-1 (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-GSK-3β (Ser9) 
and total GSK-3β (Cell Signaling Technology, Danvers, MA). Cy3-conjugated secondary 
antibodies were from Sigma (St. Louis, MO). TGF-β1 was from R&D Systems 
(Minneapolis, MN). Endothelial cell growth supplement was from Sigma (St. Louis, MO). 
The kinase inhibitors used were: c-Abl inhibitor imatinib mesylate from LC Laboratories 
(Woburn, MA), p38 MAP kinase inhibitor SB 203580, the JNK MAP kinase inhibitor SP 
600125 and the Erk1/2 specific upstream inhibitor PD 98059 from Cayman Chemical (Ann 
Arbor, MI). The PI-3 kinase inhibitor LY294002 was from Cell Signalling (Danvers, MA) 
and the PKC-δ inhibitor rottlerin was from Alexis Biochemical (San Diego, CA). 
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Isolation and culture of pulmonary endothelial cells 
Pulmonary EC were isolated from C57BL/6 mice (8–12 weeks old) following IACUC 
approval with a modification of the Marelli-Berg method (22,23). Briefly, lungs were 
harvested, mechanically minced, and enzymatically digested with collagenase (30 mg/ 
100ml; Worthington, Lakewood, NJ) in 0.1% BSA at 37 °C for 1 h with constant gentle 
mechanical agitation. The resulting mixture of cells was filtered through a sterile 75 μm cell 
strainer (BD Biosciences, San Diego, CA). The single cell suspension obtained was 
incubated with rat anti-mouse CD34 antibody (1:50) at 4 °C for 45 min with gentle shaking, 
followed by magnetic bead separation using goat anti-rat IgG-conjugated microbeads (1:5, 
Miltenyi Biotec, Auburn, CA, USA). The isolated EC were cultured in DMEM with 20% 
FBS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium 
pyruvate, 20 mM HEPES, 1% non-essential amino acids, 100 μg/ml endothelial cell growth 
supplement and 50 U/ml heparin in 2% gelatin pre-coated tissue culture dishes. Following 
expansion to 70–80% confluence (3–5 days), the cells were resuspended and a second 
immunologic separation carried out using rat anti-mouse CD102 antibody. The resulting 
cells were plated and their endothelial phenotype confirmed by cellular uptake of DiI- 
acetylated LDL (DiI-AcLDL, Biomedical Technologies, Stoughton, MA) and cell 
morphology. The proportion of cells taking up DiI-AcLDL compared to the number of cell 
nuclei representing the entire cell population, was used to assess the purity of the isolated 
EC populations. For TGF-β treatment, pulmonary EC were washed with serum-free medium 
and then incubated with 10 ng/ml TGF-β1 in endothelial cell culture medium containing 
0.5% FBS. The medium was changed and additives replenished every 2 days. Phase-contrast 
and fluorescent images were obtained using an inverted microscope with SpotBasic software 
(Sterling Heights, MI). 
 
Immunofluorescence staining 
Pulmonary EC were seeded onto glass culture slides and treated as described above. One or 
3 days following TGF-β1 treatment, cells were fixed with 3.7% formaldehyde and 
permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 3 min. Slides 
were washed with PBS and blocked with 1% bovine serum albumin in PBS at room 
temperature for 1 h and then they were incubated with primary antibodies against α-SMA 
(1:200) or Snail 1 (1:50). Slides were then incubated with Cy3-conjugated secondary 
antibodies (1:500). 
 
Protein precipitation from cell culture medium 
The conditioned culture media from primary pulmonary EC that were treated with or 
without TGF-β1 for 3 days was mixed with 9 volumes of 100% ethanol, incubated at −80 °C 
for 15 min and subsequently centrifuged at 13,000 rpm for 15 min at 4°C. The pellet was 
resuspended in PBS and protein concentrations were assessed using the BCA assay kit (Bio- 
Rad, Hercules, CA). 
 
Western blot analysis 
Primary pulmonary EC were treated for 72 h with TGF-β1 (10 ng/ml) with or without small 
molecule kinase inhibitors as indicated. Following treatment, the cells were washed with 
cold PBS, harvested with a cell lifter, centrifuged and lysed with RIPA lysis buffer (25 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% Na deoxycholate and 0.1 % SDS) 
supplemented with a complete protease inhibitor cocktail (Roche Diagnostics, Indianapolis, 
IN). Cellular proteins were resolved by SDS-polyacrylamide gel electrophoresis, and 
transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA). Blots were blocked for 
1 h in Tris-buffered saline (TBS)-Tween (10 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 
0.1% Tween 20) containing 5% nonfat dry milk (BioRad, Hercules, CA). Then, membranes 
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were incubated overnight at 4°C with mouse monoclonal α-SMA antibody (1:200) or rabbit 
polyconal Snail-1 antibody (1:1000), rabbit phospho-GSK-3β (Ser9) antibody (1:1000) or 
GAPDH polyclonal rabbit antibody (1:200) primary antibodies in a 5% nonfat dry milk/ 
TBS-Tween solution. Membranes were then washed with TBS-Tween, and incubated for 1 h 
with the appropriate horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare, UK). Signal was detected with an enhanced chemiluminescence detection kit 
(Pierce, Rockford, IL) and collected on an autoradiography film (Denville Scientific, 
Metuchen, NJ). The signals were quantified using NIH Image J software. 
 
Treatment with small molecule kinase inhibitors 
Primary EC cultures were treated for 72 h with TGF-β1, in the presence or absence of the 
following kinase inhibitors: p38 MAP kinase inhibitor SB 203580 (5μM), JNK MAP kinase 
inhibitor SP 600125 (1 μM), Erk1/2 specific upstream inhibitor PD 98059 (5μM), PI-3 
kinase inhibitor LY294002 (5 μM), PKC-δ inhibitor rottlerin (0.5 μM), or c-Abl kinase 
inhibitor imatinib mesylate (2μg/ml). 
 
RNA interference 
Transfection of short interfering RNAs (siRNAs) was performed in 6-well tissue culture 
plates employing the HiPerFect reagent (Qiagen, Valencia, CA). Two different sequences 
were targeted and the final concentration of the siRNAs used was 5 nM. Following siRNA 
transfection, 10 ng/ml TGF-β1 was added to the media, and incubation was continued for 72 
h. The siRNA target sequences were: murine Snail-1: 5′-CAG TTT ATT GAT ATT CAA 
TAA-3′ and 5′-ATG GTT AAT TTTA TAT ACT AAA-3′; murine c-Abl: 5′-CTC GAT 
GGA ACT CCA AGG AAA-3′ and 5′-CAG GCC CAC ACT GAT CAC CTA-3′; murine 
PKC-δ: 5′-AGG GAA GAC ACT GGT ACA GAA-3′ and 5′-CCG ATT CAA GGT TTA 
TAA CTA-3′. Control siRNA was obtained from Qiagen and was transfected employing the 
same conditions. 
 
Semi-quantitative reverse transcription (RT)-PCR 
Treated primary pulmonary EC were harvested, washed in cold PBS, and processed for 
RNA extraction (RNeasy kit; Qiagen). Total RNA (1 μg) was reverse-transcribed using 
Superscript II reverse transcriptase (Invitrogen) to generate first strand cDNA. The primers 
for RT-PCR were designed using Vector NTI 5 software (Invitrogen) and validated for 
specificity. The following primers were used: Snail-1; forward, 5′-ACC TTC CAG CAG 
CCC TAC GA-3′, reverse, 5′-AGC GTG TGG CTT CGG ATG TG-3′. Snail-2; forward, 5′- 
ACT ACA GCG AAC TGG ACA CA-3′, reverse, 5′-CTG GAG AAG GTT TTT GGA 
GCA-3′. GAPDH; forward, 5′-TGT GGA TGG CCC CTC TGG AA-3′, reverse, 5′-CGG 
CAT CGA AGG TGG AAG AG-3′. RT-PCR was performed following a standard 
amplification protocol. The products were electrophoresed on 1% agarose gels and stained 
with ethidium bromide. The reaction products were visualized with a FluorImager 
(Molecular Dynamics, Sunnyvale, CA). Images were quantitated using NIH Image J 
software and the signals were normalized to those obtained for loading controls. The values 
for the untreated control samples were set as 1 and all the experimental values were 
expressed as a multiple thereof. 
 
Quantitative real time PCR 
Real-time PCR was performed using SYBR green employing a standard amplification 
protocol on a ABI 7900 HT Fast Real-time PCR system. The following primers were used: 
α-SMA, forward, 5′-GTG GCC CCT GAA GAG CAT C-3′, reverse, 5′-AAT CTG GGT 
CAT TTT CTC CCG-3′. Collagen I, forward, 5′-GCA TGG CCA AGA AGA CAT CC-3′, 
reverse, 5′-TCC ACG TCT CAC CAT TGG G-3′. 18S, forward, 5′-CGG CTA CCA CAT 
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CCA AGG AA-3′, reverse, 5′-GGG CCT CGA AAG AGT AAT GT-3′. The primers for 
Snail-1 amplification were the same as those used for RT-PCR (see above). To confirm the 
amplification specificity, the PCR products were subjected to melting temperature 
dissociation curve analysis. No amplification and no template controls were examined in 
parallel. The cycle number (CT) at which amplification entered the exponential phase was 
determined and used as an indicator of the amount of target RNA produced in the reactions. 
The control experiment levels were set as 1 and all the other values expressed as a multiple 
thereof. 
 
Statistical analysis 
Data are expressed as means ± SD. Means of different groups were compared using one-way 
analysis of variance. Statistical analysis was performed by using unpaired Student’s t test. A 
value of p < 0.05 was considered to be statistically significant. 
 
Results 
 
Isolation and characterization of murine pulmonary EC 
To ensure that there were no other contaminating cells, we performed a sequential 
immunomagnetic isolation procedure using an initial purification with anti-CD34 antibody 
followed by expansion in monolayer cell culture and a second immunomagnetic purification 
with CD-102 antibodies. These two antibodies are reported to be specific for endothelial 
cells. This procedure yielded 1–1.5 million pure EC from each pair of lungs with 95% 
viability. The pulmonary EC monolayer cultures showed classical EC cobblestone 
morphology and following confluency displayed the formation of characteristic capillary 
tubes (Figures 1A and 1B). The endothelial phenotype of the cultured cells was confirmed 
by uptake of DiI-Ac-LDL (Figure 1C), a specific procedure to identify EC in culture (24). 
The proportion of DiI-AC-LDL- positive cells indicated that greater than 99% of cells in the 
preparation were EC (Figure 1C and 1D). 
 
TGF-β1 induction of a myofibroblast phenotype in primary pulmonary EC 
Primary pulmonary EC cultures treated with TGF-β1 for 72 h lost their characteristic 
cobblestone-like morphology and expressed the myofibroblast-specific protein α-SMA 
(Figure 2A and 2B). Western blot analysis confirmed induction of α-SMA in these cells, 
whereas in cells cultured without TGF-β1 there was no detectable α-SMA expression 
(Figure 2C). We next examined whether TGF-β1-treated EC also displayed expression of 
the fibroblast phenotype-specific marker type I collagen. In the untreated cells there was no 
evidence of collagen I expression, whereas treatment with TGF-β1 induced significant 
(p<0.05 when compared with control cells) collagen I expression (Figure 2D). The TGF-β1- 
treated EC also lost the endothelial cell marker VE-cadherin. As expected, untreated cells 
displayed high expression of VE-cadherin, whereas treatment with TGF-β1 caused a marked 
and significant (p<0.05 compared with control cells) reduction in VE-cadherin expression 
(Figure 2E). We next studied the time course of α-SMA and collagen I mRNA expression 
following TGF-β exposure by quantitative real-time PCR. The results showed a marked 
increase in α-SMA mRNA expression at 12 h (p<0.05 when compared with control) with a 
further increase at 24 h. In contrast, collagen I mRNA displayed a significant increase only 
after 24 h (p<0.05 when compared with control, Figure 2F). 
 
TGF-β1 induction of Snail-1 expression in primary pulmonary EC 
The family of Snail proteins has been shown to regulate EMT and cell behavior during a 
variety of developmental processes (25–27). Therefore, we tested whether Snail-1 also 
participates in EndoMT in pulmonary EC. Snail-1 expression examination by 
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immunofluorescence staining showed a very low level of expression in untreated cells that 
was confined to the nuclei. In contrast, TGF-β1 treatment significantly increased Snail-1 
expression (p<0.05 when compared with control cells) in pulmonary EC (Figure 3A and 
3B). The results were confirmed by assessment of Snail-1 mRNA levels by RT-PCR. In 
untreated cells we observed a very low level of basal expression of Snail-1, however, TGF- 
β1 treatment caused a potent stimulation of its expression. In contrast, Snail-2 showed 
higher constitutive levels of expression, however, there was no stimulation of its expression 
following TGF-β1 treatment (Figure 3C). Further quantification of mRNA expression by 
quantitative real-time PCR showed that following 24 h TGF-β1 treatment, there was a 
significant increase in Snail-1 mRNA expression (p<0.05 when compared with control cells; 
Figure 3D). 
 
Effects of kinase inhibitors on TGF-β1-induced α-SMA and Snail-1 expression in primary 
pulmonary EC 
To examine the intracellular signaling pathways that may be involved in the induction of α- 
SMA and Snail-1 expression by TGF-β1, we treated the cells with a variety of small 
molecule kinase inhibitors. The results employing a p38 MAP kinase inhibitor (SB 203580), 
a JNK MAP kinase inhibitor (SP 600125), or an Erk1/2 specific upstream inhibitor (PD 
98059) with or without TGF-β1 are shown in Figure 4A. Treatment with either the p38 
MAP kinase inhibitor or the JNK MAP kinase inhibitor decreased but did not abrogate TGF- 
β1-induced α-SMA and Snail-1 expression. Treatment with the Erk1/2 inhibitor had no 
significant effects. Studies with the PI3K inhibitor (LY294002) or the PKC-δ inhibitor 
(rottlerin) with or without TGF-β1 are shown in Figure 4B. Treatment with the PKC-δ 
inhibitor almost completely abrogated TGF-β1-induced α-SMA and Snail-1 expression, 
whereas treatment with the PI-3K inhibitor had no detectable effects. 
 
Imatinib mesylate abrogates TGF-β1-inducedα-SMA expression in primary pulmonary EC 
To examine the participation of c-Abl on TGF-β1-induced α-SMA expression pulmonary 
EC were treated with TGF-β1 in the presence or absence of imatinib mesylate for 72 h. As 
shown in Figure 5A, imatinib mesylate almost completely abolished TGF-β1-induced α- 
SMA expression. Moreover, in the few cells that displayed α-SMA staining following 
treatment with imatinib, α-SMA was distributed diffusely in the cells and did not organize 
into any typical α-SMA stress fibres. Western blot assay confirmed that imatinib mesylate 
caused a potent decrease in TGF-β1-induced α-SMA expression (p<0.05 compared with 
control cells; Figure 5B). 
 
Effects of imatinib mesylate on TGF-β1-induced Snail-1 mRNA and protein expression in 
primary pulmonary EC 
To examine whether the effects of imatinib mesylate on TGF-β1-induced α-SMA expression 
were accompanied by parallel changes in Snail-1 expression, we examined Snail-1 transcript 
levels using reverse transcription PCR. As shown in Figure 5C, TGF-β1 induced a marked 
increase in Snail-1 expression, and treatment with imatinib mesylate reduced significantly 
(p<0.05) these levels to almost baseline values. The effects of imatinib mesylate on TGF-β1- 
induced Snail-1 expression were confirmed by Western blots (p<0.05 compared with control 
cells; Figure 5D). To determine whether the potent inhibition of TGF-β induced EndoMT by 
imatinib mesylate was mediated through blockade of the canonical Smad2/3 cascade, we 
measured phospho-Smad2 levels. Although TGF-β1 significantly induced phospho-Smad2 
levels, this effect was not suppressed by imatinib mesylate (data not shown), indicating that 
the canonical Smad pathway does not participate in imatinib inhibition of TGF-β1-induced 
Snail-1 expression. 
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Effects of Snail-1 knockdown on TGF-β1 induced-SMA expression in primary pulmonary 
EC 
To determine whether Snail-1 is required for TGF-β1 induced α-SMA expression, we 
transfected Snail-1 siRNA into primary pulmonary EC followed by treatment with TGF-β1. 
As control, we transfected siRNA consisting of a sequence that has no known homology to 
any mammalian gene. As shown in Figure 5E, transfection of Snail-1 siRNA caused a 
significant (p<0.05) inhibition of TGF-β1-inducedα-SMA expression. 
 
Effects of MAP kinase, c-Abl, and PKC-δ inhibition on TGF-β1-induced GSK-3β 
phosphorylation 
Numerous previous studies have demonstrated that GSK-3β phosphorylation at residue Ser9 
plays a crucial role in the regulation of EMT (27). To examine whether GSK-3β 
phosphorylation is also important in EndoMT we studied the changes in TGF-β1-induced 
GSK-3β Ser9 phosphorylation following treatment with various kinase inhibitors. As shown 
in Figure 6A and 6B, TGF-β1 caused potent stimulation of Ser9 GSK-3β phosphorylation 
and treatment with the MAP kinase inhibitors did not have any effect. In contrast, both the 
c-Abl inhibitor imatinib mesylate and the PKC-δ inhibitor rottlerin almost completely 
abrogated the TGF-β1-induced GSK-3β Ser9 phosphorylation (p<0.05 for both compounds 
when compared with the TGF-β1 treated group). 
 
Effects of c-Abl, and PKC-δ knockdown on TGF-β1 induced-SMA and Snail-1 expression in 
primary pulmonary EC 
To further confirm the role of c-Abl and PKC-δ in TGF-β1 induced SMA expression, we 
transfected c-Abl and PKC-δ siRNA into primary pulmonary EC followed by treatment with 
TGF-β1. Preliminary experiments (data not shown) indicated that transfection of the 
selected siRNA caused nearly complete inhibition of expression of the corresponding genes. 
As shown in Figure 6C and 6D, knockdown of either c-Abl or PKC-δ employing siRNA 
caused a potent inhibition of TGF-β1-induced α-SMA and Snail-1 expression. 
 
Discussion 
 
One of the most characteristic histopathologic alterations in SSc is a severe 
fibroproliferative vasculopathy affecting the microvasculature as well as some larger 
vessels. The proliferative vasculopathy of SSc has two distinct components. The first one is 
a marked proliferation of smooth muscle cells in the media of medium size and small size 
arterioles, a process which plays a crucial role in SSc-associated pulmonary hypertension. 
The second component is most prominent in the small arterioles of parenchymal organs such 
as the lungs and is characterized by the subendothelial accumulation of activated fibroblasts 
or myofibroblasts and the production of abundant fibrotic tissue. The origin of mesenchymal 
cells responsible for the fibrotic microvascular occlusion in SSc is not known but recent 
studies have suggested that at least some of these cells may result from EndoMT, i.e., the 
transdifferentiation of EC into subintimal fibroblasts induced by locally-secreted cytokines 
and growth factors. 
 
The purpose of our study was to examine the transdifferentiation of pulmonary EC into 
mesenchymal cells in vitro and the signaling pathways involved in this process. Our results 
have shown that: (1) primary murine pulmonary EC undergo EndoMT in response to TGF-β 
with initiation of expression of α-SMA and assembly of typical intracellular α-SMA stress 
fibers, and loss of VE-cadherin in vitro; (2) TGF-β induction of EndoMT was associated 
with a strong upregulation in the expression of the transcriptional repressor Snail-1 
indicating that Snail-1 is directly involved TGF-β-induced α-SMA expression; and (3) 
induction of α-SMA expression in pulmonary EC was mediated by c-Abl and PKC-δ, as 
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specific inhibition of their kinase activity with imatinib mesylate and rottlerin, respectively, 
or by knockdown of their corresponding transcripts with specific siRNA abrogated the 
marked increase in TGF-β induced α-SMA and Snail-1 expression and protein levels. 
 
EndoMT is a recently recognized process of non-malignant cellular transdifferentiation in 
which highly differentiated endothelial cells acquire the expression of specific mesenchymal 
cell markers such as α-SMA, vimentin, and type I procollagen, lose the expression of VE- 
cadherin, and change their typical endothelial cell morphology becoming elongated and 
acquiring the ability to migrate into surrounding tissues. This process, initially identified 
during development of the cardiac atrioventricular cushion and the cardiac septum in 
embryonic life, has more recently been demonstrated to occur in adult tissues and to play an 
important role during the development of pathologic cardiac, pulmonary and renal fibrosis 
(5–12). Indeed, by using endothelial lineage tracing in transgenic mice, it was shown that 
30–50% of all myofibroblasts in renal fibrosis arise from endothelial cells via EndoMT 
(9,10) and that a significant amount of fibroblasts in bleomycin-induced lung fibrosis are EC 
derived (11). 
 
Given the crucial role of TGF-β in the development of tissue fibrosis and its participation in 
the pathogenesis of numerous fibrotic diseases, we examined the mechanisms involved in 
the induction of EndoMT by this pleotropic growth factor and studied the intracellular 
transduction pathways involved in this process employing primary pulmonary EC in culture. 
We confirmed the occurrence of EndoMT following TGF-β and demonstrated that the 
downstream signaling pathway initiated by TGF-β ligation resulted in strong upregulation of 
the transcriptional repressor Snail-1. Snail-1 is a zinc-finger transcription factor that causes 
potent inhibition of the E-cadherin gene transcription in cultured cells (28,29) and plays an 
important in the process of EMT (26,27). Our observation that TGF-β1 also induced Snail-1 
expression in EC confirm previous studies (30) and indicate that EndoMT and EMT very 
likely share similar molecular mechanisms. 
 
The intracellular signaling studies described here showed that TGF-β1-induced EndoMT 
involving the participation of c-Abl and PKC-δ. The potent inhibitory effects of imatinib 
mesylate and rottlerin were shown to be accompanied by inhibition of phosphorylation of 
the Ser9 residue in GSK-3β. These results are in agreement with recent studies 
demonstrating that phosphorylation of this specific Ser9 residue in GSK-3β inactivates the 
kinase which in turn induces the nuclear accumulation of Snail-1 as well as a profound 
increase in the expression of its corresponding gene and in stabilization of the protein (31– 
33). These events result in a marked increase in the transcriptional effects of Snail-1 and 
eventually in the increased expression of mesenchymal cell proteins such as α-SMA and 
collagen I. 
 
Imatinib mesylate, a small-molecule tyrosine kinase inhibitor widely used for the treatment 
of chronic myelogenous leukemia has recently been proposed as a novel antifibrotic therapy 
(34–36). It has been shown to have anti-fibrotic effects in mice models of systemic fibrosis 
(37–38), and it also can attenuate bleomycin-induced pulmonary fibrosis (34,39). On the 
other hand, several studies have shown that PKC-δ participates in the pathogenesis of tissue 
fibrosis in SSc (40,41). Here, by using primary pulmonary EC, we showed that imatinib 
mesylate can inhibit TGF-β1-induced EndoMT and Snail-1 expression. Furthermore, our 
studies showed that inhibition of PKC-δ with the highly selective inhibitor rottlerin also 
abrogated EndoMT induction by TGF-β and blocked the increased expression of α-SMA 
and Snail-1 indicating that this kinase is also intimately improved in this process. The role of 
PKC-δ was confirmed employing siRNA knockdown which caused similar abrogation of α- 
SMA and Snail-1 expression as rottlerin (Figure 6). These latter results indicated that the 
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effects of rottlerin were related to specific inhibition of PKC-δ and were not the result of 
other non-specific effects. 
 
In conclusion, the results described here identify c-Abl and PKC-δ as two important 
components of the process of TGF-β-induced EndoMT and suggest that targeting these 
components may be a feasible therapeutic goal to modify crucial steps in the development of 
SSc fibroproliferative vasculopathy and may also be of value in the treatment of other 
fibrotic disorders in which EndoMT plays a pathogenetic role. Obviously, subsequent 
preclinical studies employing suitable animal models will be required to further support the 
potential therapeutic role of c-Abl and PKC-δ inhibition for the proliferative vasculopathy of 
SSc and other disorders. 
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Figure 1. Characterization of pulmonary EC 
A. Phase contrast of pulmonary EC in culture isolated employing sequential anti-CD34 and 
anti-CD102 antibody selection. B. Characteristic tube-formation at confluence. C. Ac-LDL 
uptake assay. D. Cells in the same field as IC stained with DAPI for nuclear staining. 
Pulmonary EC display cobblestone morphology, form multicellular tubes (arrow) and 
express high levels of Ac-LDL confirming their endothelial phenotype. Size bar = 100μm 
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Figure 2. TGF-β1 induced α-SMA expression in primary pulmonary EC 
A, B. Primary pulmonary EC were treated with TGF-β1 for 72 h, fixed and stained with α- 
SMA. Note the phenotypic change of EC which acquire a fibroblast-like appearance and 
initiate expression of α-SMA. C, D, E. Primary lung EC were treated with TGF-β1 for 72 h, 
and cell lysates were electrophoresed and probed in Western blots with specific antibodies to 
α-SMA (C), collagen I (D) and VE-cadherin (E). GAPDH was used as loading control. 
Fluorescence density of α-SMA expression and quantitative densitometry of Western blots 
were analyzed using NIH Image J software. F. Quantitative real-time PCR analysis of TGF- 
β1 induction of α-SMA and collagen I mRNA expression in primary pulmonary EC. 
Amplification of 18S RNA was used as internal control. Data represent the mean ± SD of 
one of two independent experiments in which each sample was analyzed in triplicate. *p < 
0.05 when compared with controls. Size bar = 50μm. 
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Figure 3. TGF-β1 induced Snail-1 expression in primary pulmonary EC 
A, B. Primary pulmonary EC were treated with TGF-β1 for 24 h, fixed and stained by 
indirect immunofluorescence with Snail-1. Note a marked increase in expression of Snail-1 
following treatment with TGF-β. B. Fluorescence density of α-SMA expression analyzed 
using NIH Image J software. C. Primary pulmonary EC were treated with TGF-β1 for 72 h. 
RNA was purified and reverse transcribed and assessed by PCR for Snail-1 and Snail-2 
expression. GAPDH was used as control. Note very low level basal expression of Snail-1. 
Treatment with TGF-β1 increased Snail-1 expression. In contrast, Snail-2 levels displayed 
higher constitutive expression and did not show any change following TGF-β treatment. D. 
Quantitative real-time PCR analysis of TGF-β1 induction of Snail-1 mRNA expression. The 
data represent the mean ± SD of one of two independent experiments in which each sample 
was analyzed in triplicate (*p < 0.05 when compared with controls). Size bar = 50μm 
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Figure 4. Effect of kinase inhibitors on TGF-β1-induced α-SMA and Snail-1 expression in 
primary pulmonary EC 
Primary pulmonary EC were treated with either 5μM p38 MAP kinase inhibitor SB 203580, 
1μM JNK MAP kinase inhibitor SP 600125, or 5μM Erk1/2 specific upstream inhibitor PD 
98059 (A), or with 5μM PI3-kinase3 inhibitor LY294002 or 0.5μM PKC-δ inhibitor rottlerin 
(B) in the presence or absence of TGF-β1 for 72 h, then cell lysates were probed in Western 
blots for α-SMA. GAPDH was used as loading control. Note that SB 203580 and SP 600125 
decrease TGF-β1-induced α-SMA expression, treatment with the PKC-δ inhibitor rottlerin 
almost completely abolished TGF-β1-induced α-SMA expression, whereas treatment with 
either the Erk1/2 inhibitor or the PI-3 kinase inhibitor had no significant effects. The 
quantitative densitometry of α-SMA was analyzed using NIH Image J software and the data 
represent one of two independent experiments *p < 0.05 when compared with the TGF-β1- 
treated group. 
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Figure 5. Effect of imatinib mesylate on TGF-β1-induced α-SMA and Snail-1 expression in 
primary pulmonary EC 
A. Primary pulmonary EC were treated with imatinib with or without TGF-β1 for 72 h, fixed 
and stained with α-SMA. Imatinib significantly decreased TGF-β1-induced α-SMA 
expression. Also note that in imatinib-treated cells, α-SMA was distributed homogenously 
and did not organize into α-SMA stress fibers. B, C. Cell lysates were probed by Western 
blots for α-SMA (B) and Snail-1 (C). GAPDH was used as loading control. Quantitative 
densitometry was analyzed using NIH Image J software and the data represent one of two 
independent experiments in which each sample was analyzed in triplicate. D. Primary 
pulmonary EC were treated with imatinib with or without TGF-β1 for 72 h. Transcript levels 
were assessed by PCR. GAPDH was used as control. The quantitative densitometry was 
analyzed using NIH Image J software. Note that imatinib significantly downregulated 
Snail-1 protein levels (5C) and mRNA expression (5D). E. Primary EC were transfected 
with Snail-1 siRNA or with control siRNA followed by TGF-β1 treatment for 72 h, cell 
lysate proteins were probed with α-SMA. GAPDH was used as loading control. The data 
represent one of two independent experiments. *p < 0.05 when compared with TGF-β1- 
treated group. Size bar = 50μm. 
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Figure 6. Effect of MAP kinase, c-Abl, and PKC-δ inhibition on TGF-β1-induced GSK-3β 
phosphorylation 
A, B. Primary pulmonary EC were treated with 5μM p38 MAP kinase inhibitor SB 203580, 
5 μM JNK inhibitor SP 600125 (A), or 2μg/ml c-Abl inhibitor imatinib mesylate or 0.5 μM 
PKC-δ inhibitor rottlerin (B) for 72 h then cell lysates were probed in Western blots with 
phospho-GSK-3β (Ser9) and total GSK-3β antibodies. Note that the MAP kinase inhibitor 
did not have any effect on TGF-β1-induced GSK-3β Ser9 phosphorylation (A) whereas, both 
the c-Abl inhibitor imatinib and the PKC-δ inhibitor rottlerin almost completely abrogated 
TGF-β1-induced Ser9 GSK-3β phosphorylation (B). C, D. Primary EC were transfected with 
either c-Abl or PKC-δ specific siRNA or with control siRNA followed by TGF-β1 treatment 
for 72 h. Cell lysates were probed in Western blots for α-SMA and Snail-1. GAPDH was 
used as loading control. The data represent one of two independent experiments. The 
quantitative densitometry was analyzed using NIH Image J software. *p < 0.05 when 
compared with the TGF-β1-treated group. 
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